Published in Blood Weekly, January 9th, 2003
This trial will be conducted in those patients who are in high-risk situations for the development of thromboses. The first patient has received treatment in the study. This study is expected to be the final clinical trial before submission for European registration.
The trial is an open-label, single-arm study including at least 12 patients. This is a multinational study conducted primarily in Europe in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.